Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aurora Cannabis Inc.NASDAQ: ACB
Cash & Equivalents · Q4 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 38.8% from a year ago
Cash & equivalents stood at CA$112.77M at the end of Q4 FY2026, down 38.8% from a year earlier and up 100.1% from the prior quarter. Over 3 fiscal years it compounded at -27.9% a year.
Context
- Cash & equivalents amounted to 18.7% of total assets at the end of Q4 FY2026, down 3.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -38.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CAD · from the balance sheet
- Latest · FY2026
- 112.77M CAD
- Year-over-year change
- -38.8%
- 4-year CAGR
- -21.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 112.77M | -38.8% |
| FY2025 | 2025-03-31 | 184.26M | +2.6% |
| FY2024 | 2024-03-31 | 179.53M | -40.3% |
| FY2023 | 2023-03-31 | 300.86M | +0.0% |
| FY2022 | 2022-06-30 | 300.86M | — |
Cash & Equivalents vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -38.8% is the lowest of 10, against a peer median of +5.2%.
- Cash & equivalents amounts to 18.7% of total assets for ACB, versus a peer median of 23.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$364.68M CAD | +220.4% | -8.7% | 32.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M USD | -6.1% | +89.8% | 60.8% |
| Mar 2026 | $220.47M USD | +103.2% | -31.0% | 50.7% | |
| Mar 2026 | $123.65M USD | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | CA$112.77M CAD | -38.8% | -27.9% | 18.7% | |
| Mar 2026 | CA$54.08M CAD | +310.3% | — | 10.3% | |
| Apr 2026 | CA$36.51M CAD | +5.2% | +24.0% | 10.5% | |
| Mar 2026 | $34.48M USD | +0.2% | +110.2% | 49.2% | |
| Mar 2026 | $28.66M USD | -5.6% | -23.9% | 14.4% | |
| Dec 2025 | $17.47M USD | — | — | 7.5% | |
| Mar 2026 | $4.31M USD | +27.5% | -48.1% | 4.4% | |
| Peer median (excluding ACB) | — | +5.2% | -3.7% | 23.5% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 300.86M | 300.86M | 179.53M | 184.26M | 112.77M |
| Short-term Investments | 0 | 0 | 4.04M | 550.82K | 52.35M |
| Net Receivables | 41.35M | 41.35M | 45.49M | 42.23M | 44.69M |
| Inventory | 128.83M | 128.83M | 186.7M | 237.72M | 175.53M |
| Other Current Assets | 8.92M | 8.92M | 11.58M | 10.82M | 13.14M |
| Total Current Assets | 479.96M | 479.96M | 427.35M | 475.58M | 398.48M |
| Property, Plant & Equipment (Net) | 322.99M | 322.99M | 294.84M | 266.57M | 124.01M |
| Goodwill | 18.72M | 18.72M | 43.26M | 43.62M | 26.72M |
| Intangible Assets | 59.68M | 59.68M | 40.92M | 44.9M | 31.52M |
| Long-term Investments | 13.75M | 13.75M | 6.35M | 5.23M | 15.82M |
| Tax Assets | 15.5M | 15.5M | 15.37M | 4.19M | 2.46M |
| Other Non-current Assets | 15.79M | 15.79M | 12.05M | 7.68M | 3.63M |
| Total Non-current Assets | 446.42M | 446.42M | 412.79M | 372.19M | 204.16M |
| Total Assets | 926.38M | 926.38M | 840.14M | 847.77M | 602.64M |
| Account Payables | 21.94M | 21.94M | 20.36M | 27.46M | 9.33M |
| Short-term Debt | 147.56M | 147.56M | 57.32M | 26.74M | 5.74M |
| Tax Payables | 1.13M | 161K | 4.05M | 10.11M | 0 |
| Deferred Revenue | 1.74M | 1.74M | 1.69M | 1.07M | 1.27M |
| Other Current Liabilities | 53.73M | 53.73M | 28.4M | 27.87M | 30.12M |
| Total Current Liabilities | 237.75M | 237.75M | 124.84M | 110.23M | 67.1M |
| Long-term Debt | 36.17M | 36.17M | 4.91M | 39.96M | 0 |
| Deferred Tax Liabilities | 16.75M | 16.75M | 16.22M | 1.89M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 71.3M | 71.3M | 53.69M | 53.32M | 4.21M |
| Total Non-current Liabilities | 166.89M | 166.89M | 112.38M | 132.45M | 22.38M |
| Total Liabilities | 404.64M | 404.64M | 237.22M | 242.67M | 89.49M |
| Common Stock | 6.84B | 6.84B | 6.98B | 6.95B | 7.03B |
| Retained Earnings | (6.29B) | (6.29B) | (6.38B) | (6.33B) | (6.46B) |
| Accumulated OCI | (58.33M) | (58.33M) | (43.78M) | (55.91M) | (214.15M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 31.06M | 31.06M | 42.17M | 41.18M | 0 |
| Total Equity | 521.74M | 521.74M | 602.92M | 605.09M | 513.15M |
| Total Debt | 226.41M | 226.41M | 99.78M | 103.98M | 23.92M |
| Net Debt | (74.45M) | (74.45M) | (79.75M) | (80.28M) | (88.85M) |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.